Author: OurCrowd

[Quantum Machines in PR Newswire] Quantum Machines expands global presence with new headquarters in Germany

Oct 25, 2023 |

TEL AVIV, Israel and STUTTGART, Germany, Oct. 25, 2023 /PRNewswire/ — Quantum Machines (QM), the provider of breakthrough quantum control solutions that accelerate the development of practical quantum computers, today announced the establishment of its new entity, QM Technologies GmbH, a Quantum Machines company in Germany. With the company’s German headquarters strategically located in Stuttgart, Quantum Machines continues its international expansion, leveraging access to local talent in the quantum field and benefiting from proximity to many of its European customers. Read more...

Read More

[SeeTrue in PR Newswire] SeeTrue AI, a global leader in Security Screening Solutions, signs a Cooperative Research and Development Agreement (CRADA) with the Department of Homeland Security’s (DHS)

Oct 24, 2023 |

NEW YORK, Oct. 24, 2023 /PRNewswire/ — SeeTrue, a leader in AI based security screening solutions, is collaborating with the Department of Homeland Security (DHS) Science and Technology Directorate (S&T) and the Transportation Security Administration’s (TSA) Innovation Task Force (ITF) to evaluate efficacy of its state-of-the-art AI Threat Detection Solution for implementation at security checkpoints across the USA. Read...

Read More

[VidMob in GlobeNewswire] VidMob appoints Mainardo de Nardis as Executive Chairman

Oct 24, 2023 |

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) — VidMob, the leading AI creative performance platform today announced the recent appointment of Mainardo de Nardis. In this leadership role, de Nardis will support the executive team in setting the company’s growth strategy. An acclaimed global agency leader, Mainardo de Nardis also brings deep and relevant experience that will support VidMob’s strategic agency relationships. Read more...

Read More

[MeMed in EIN Newswire] MeMed awarded US BARDA contract to demonstrate clinical utility of the FDA-cleared MeMed BV® test for distinguishing bacterial from viral infections

Oct 24, 2023 |

/EIN News/ — TIRAT CARMEL, Israel; BOSTON, MA – 24 October, 2023 – MeMed, a leader in host response technologies, is pleased to announce that it has been awarded a contract valued at $727,799 by the Division of Research, Innovation, and Ventures (DRIVe) of the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA). The contract will support the execution of a randomized controlled trial designed to build on existing clinical utility data demonstrating that MeMed BV can improve patient outcomes. Read more...

Read More